Table 2.

Pharmacokinetic Model Parameters of the Combined Ketamine-Norketamine Model.

	Estimate	SE	ω2	SE	ν2	SE
S(+)-ketamine
V1,ket (L)	17.0	1.91	-	-	0.148	0.048
95% ci	13.6 – 21.0				0.06 – 0.25
V2.ket (L)	28.3	2.97	-	-	-	-
95% ci	23.3 – 34.1
V3,ket (L)	147	10.2	0.065	0.019	0.029	0.020
95% ci	129 – 172		0.03 – 0.10		0.00001 – 0.08
Cl1,ket (L/h)	93.5	2.70	0.007	0.004	0.006	0.002
95% ci	87.6 – 98.8		0.001 – 0.02		0.002 – 0.01
F Cl1,ket*	0.13	0.03
95% ci	0.07 – 0.20
Cl2,ket (L/h)	127	12.3	-	-	-	-
95% ci	107 – 148		-		-
Cl3,ket (L/h)	91.9	5.10	0.02	0.006	-	-
95% ci	82 - 101		0.01 – 0.03		-
σ2	0.008	0.002
S(+)-norketamine
MTT (h)	0.25	0.02	0.05*	0.03*	0.02	0.01
95% ci	0.21 – 0.28		0.01 – 0.14		0.004 – 0.05
V2.nkt (L)	193	10.6	-	-	0.14	0.03
95% ci	173 – 217		-		0.09 – 0.19
Cl1,nkt (L/h)	64.9	2.81	0.03	0.01	0.03	0.01
95% ci	58.5 – 70.8		0.01 – 0.06		0.01 – 0.05
F Cl1,nkt*	2.02	0.19
95% ci	1.67 – 2.41
Cl2,nkt (L/h)	334	30.5	0.05*	0.03*	0.14	0.04
95% ci	285 - 411		0.01 – 0.14		0.07 – 0.22
σ2	0.007	0.001

^* one parameter was sufficient for the interindividual error of Cl_2,nket and MTT;

Units of the volumes are L/kg at 70 kg; units of the clearances are L/h at 70 kg;

Cl_1,ket is the clearance from compartment 1,ket;

Cl_2,ket is the clearance from compartment 2,ket;

Cl_3,ket is the clearance from compartment 3,ket;

Cl_1,nket is the clearance from compartment 1,nkt;

Cl_2,nket is the clearance from compartment 2,nkt.

Factor F denotes the significant effect of rifampicin treatment on model parameters Cl_1,nkt and Cl_2,nkt (significance level < 0.01);

MTT is mean transit time;

ν² is the interoccasion variability (in the log-domain);

σ² is the within-subject variability (in the log domain);

SE is standard error;

V_1,ket is the volume of compartment 1,ket;

V_2,ket is the volume of compartment 2,ket;

V_3,ket is the volume of compartment 3,ket;

V_2,nkt is the volume of compartment 2,nkt.

ω² is the inter-subject variability (in the log-domain).

^*P < 0.01.